1. Home
  2. JFIN vs SPRO Comparison

JFIN vs SPRO Comparison

Compare JFIN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$1.31

Market Cap

78.0M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
SPRO
Founded
2011
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.0M
67.0M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
JFIN
SPRO
Price
$1.31
$1.07
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
34.9K
★ 461.5K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
★ 61.78%
N/A
EPS Growth
N/A
★ 111.81
EPS
★ N/A
N/A
Revenue
N/A
★ $66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
★ N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$1.13
$1.08
52 Week High
$10.06
$3.08

Technical Indicators

Market Signals
Indicator
JFIN
SPRO
Relative Strength Index (RSI) 40.83 39.23
Support Level $1.26 N/A
Resistance Level $1.62 $1.28
Average True Range (ATR) 0.11 0.06
MACD 0.02 -0.01
Stochastic Oscillator 50.00 0.00

Price Performance

Historical Comparison
JFIN
SPRO

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: